Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea

Abstract Background Insurance reimbursement provisions in South Korea limit osteoporosis medication availability for patients with T-scores exceeding − 2.5. This study aimed to evaluate the financial impact and fracture prevention of continuous denosumab therapy until a T-score>-2.0 (Dmab-C strategy...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Seungju Cha, Minjeong Sohn, Hyowon Yang, Eric J. Yeh, Ki-Hyun Baek, Jeonghoon Ha, Hyemin Ku
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-01-01
coleção:	BMC Musculoskeletal Disorders
Assuntos:	Osteoporosis Denosumab Osteoporotic fracture Bone density Cost-consequence analysis, Republic of Korea
Acesso em linha:	https://doi.org/10.1186/s12891-024-07185-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!